Publication Name	World Journal of Clinical Oncology
Manuscript ID	98079
Country	China

Received	2024-08-19 08:20
Peer-Review Started	2024-06-17 12:35
To Make the First Decision
Return for Revision	2024-10-14 00:00
Revised	2024-10-21 15:14
Second Decision	2024-11-25 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-25 07:01
Articles in Press	2024-11-25 07:01
Publication Fee Transferred	2024-10-24 02:03
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-29 09:23
Publish the Manuscript Online	2024-12-11 10:19

ISSN	2218-4333 (online)
Open Access	Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Shi-Qiong Zhou, Peng Wan, Seng Zhang, Yuan Ren, Hong-Tao Li and Qing-Hua Ke
Funding Agency and Grant Number
Corresponding Author	Qing-Hua Ke, Chief Physician, PhD, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com
Key Words	Immunotherapy; Programmed cell death 1 inhibitor; Sintilimab; Chemotherapy; Metastatic; Pancreatic ductal adenocarcinoma
Core Tip	This study aimed to explore the feasibility and effectiveness of combining the programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine (combination group) vs using S-1 and gemcitabine alone (chemotherapy group) for treating liver metastatic pancreatic adenocarcinoma. The combination of programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine demonstrated effectiveness and safety for treating liver metastatic pancreatic ductal adenocarcinoma, meriting further investigation.
Publish Date	2024-12-11 10:19
Citation	<p>Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. <i>World J Clin Oncol</i> 2025; 16(2): 98079</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i2/98079.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i2.98079

Full Article (PDF)	WJCO-16-98079-with-cover.pdf
Manuscript File	98079_Auto_Edited_100352.docx
Answering Reviewers	98079-answering-reviewers.pdf
Audio Core Tip	98079-audio.wav
Biostatistics Review Certificate	98079-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	98079-conflict-of-interest-statement.pdf
Copyright License Agreement	98079-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	98079-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	98079-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	98079-non-native-speakers.pdf
Peer-review Report	98079-peer-reviews.pdf
Scientific Misconduct Check	98079-scientific-misconduct-check.png
Scientific Editor Work List	98079-scientific-editor-work-list.pdf
CrossCheck Report	98079-crosscheck-report.pdf